A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

BACKGROUND: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Avallone, Antonio, Piccirillo, Maria Carmela, Aloj, Luigi, Nasti, Guglielmo, Delrio, Paolo, Izzo, Francesco, Di Gennaro, Elena, Tatangelo, Fabiana, Granata, Vincenza, Cavalcanti, Ernesta, Maiolino, Piera, Bianco, Francesco, Aprea, Pasquale, De Bellis, Mario, Pecori, Biagio, Rosati, Gerardo, Carlomagno, Chiara, Bertolini, Alessandro, Gallo, Ciro, Romano, Carmela, Leone, Alessandra, Caracò, Corradina, de Lutio di Castelguidone, Elisabetta, Daniele, Gennaro, Catalano, Orlando, Botti, Gerardo, Petrillo, Antonella, Romano, Giovanni M., Iaffaioli, Vincenzo R., Lastoria, Secondo, Perrone, Francesco, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746902/
https://www.ncbi.nlm.nih.gov/pubmed/26857924
http://dx.doi.org/10.1186/s12885-016-2102-y

Ejemplares similares

Ejemplares similares